The Global Health Body Sounds Alert Over Critical Shortage of Obesity Medications
Under 10% of people eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it issues its inaugural guidance on the drugs.
Given more than one billion people worldwide currently obese, it is urging broader and more equitable access to these injectable treatments.
Per estimates, more than two billion will be obese by 2030 without intervention.
"Our new guidelines recognises that excess weight is a chronic disease that can be addressed with comprehensive and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant barriers to broad access to the treatments that can assist patients in reducing considerable weight, explains the organization.
Skinny Jab Supply Crisis
Despite the present most optimistic outlook, the production of such drugs would only suffice for around 100 million people – under 10% of eligible patients, according to the health organization.
The guideline calls on countries and companies to widen availability, through strategies including licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Weight-Loss Jabs Operate
The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and boost satiety so users reduce food intake.
Individuals commonly begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence points to patients may see weight return within a year of stopping the medication, as their typical appetite come back.
To be above a healthy weight increases your chance for experiencing diseases, including diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.
